Technetium pyrophosphate nuclear scintigraphy for cardiac amyloidosis: Imaging at 1 vs 3 hours and planar vs SPECT/CT

J Nucl Cardiol. 2020 Oct;27(5):1802-1807. doi: 10.1007/s12350-020-02139-8. Epub 2020 May 15.

Abstract

Background: Multi-societal consensus recommendations endorse both planar and single photon emission tomographic (SPECT) image acquisitions for the evaluation of cardiac amyloidosis. However, the correlation between planar and SPECT findings and the optimal timing of image acquisitions remain uncertain.

Methods: This is an analysis of 109 consecutive patients who underwent technetium pyrophosphate nuclear scintigraphy for the evaluation of cardiac amyloidosis. Patients were imaged at 1 and 3 hours after radiotracer injection using both planar and SPECT/CT, and the correlations between imaging protocols were compared.

Results: In the overall cohort (median age 77 years, 75% male), 33 patients had radiotracer localized to the myocardium on SPECT/CT images. There was strong correlation between 1- and 3-hour planar heart-to-contralateral lung ratios (mean difference 0.07, r = 0.94). However, there was discordance between planar image interpretation (based upon semiquantitative score and H/CL ratio) and myocardial localization of radiotracer on SPECT/CT in 17 patients (16%). The pattern of SPECT/CT uptake was identical at 1 and 3 hours in all cases (32 diffuse, 1 focal).

Conclusion: These data support the recommendation that SPECT/CT should be obtained in addition to planar images when performing nuclear scintigraphy for the detection of cardiac amyloidosis. A 1-hour planar and SPECT/CT protocol appears optimal.

Keywords: Cardiomyopathy; SPECT; amyloid heart disease; heart failure; image analysis; image interpretation.

Publication types

  • Comparative Study

MeSH terms

  • Aged
  • Aged, 80 and over
  • Amyloid Neuropathies, Familial / complications*
  • Amyloid Neuropathies, Familial / diagnostic imaging*
  • Cardiomyopathies / diagnostic imaging*
  • Cardiomyopathies / etiology
  • Cardiomyopathies / metabolism
  • Cohort Studies
  • Female
  • Humans
  • Male
  • Radiopharmaceuticals / pharmacokinetics*
  • Reproducibility of Results
  • Single Photon Emission Computed Tomography Computed Tomography*
  • Technetium Tc 99m Pyrophosphate / pharmacokinetics*
  • Time Factors

Substances

  • Radiopharmaceuticals
  • Technetium Tc 99m Pyrophosphate

Supplementary concepts

  • Amyloidosis, Hereditary, Transthyretin-Related